Adebrelimab
CLDN18.2-positive Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the CLDN18.2-positive Advanced Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | CC |
Shr-A1904 Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | CC |
Capecitabine Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →